Bionomics initiates Phase II clinical study of BNC210 for the treatment of anxiety and depression

Posted: 22 April 2015 |

Bionomics has initiated a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression…

Bionomics Limited has initiated a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression.


The study will use functional magnetic resonance imaging (fMRI) to assess the effects of BNC210 on brain activity in patients suffering from anxiety.

“BNC210 has the potential to significantly improve the lives of anxiety sufferers, and we believe that with effective management of anxiety there is the potential to reduce the huge impact of the disease on societal and healthcare resources,” said Dr. Deborah Rathjen, Bionomics’ CEO and Managing Director.

“Currently, there is a large unmet medical need for fast-acting anxiolytic agents that lack the side effects observed with existing treatments, which include sedation and addiction, as well as negative side effects on memory and body movement. Bionomics’ commitment to the rapid development of BNC210 is indicative of its significant potential as an improved therapeutic for the treatment of anxiety.”

Results from the study of BNC210 are expected in Q3 2016

The double-blinded, placebo and lorazepam-controlled, four-way crossover single-centre Phase II study (BNC210.006) will be conducted in 24 patients with untreated Generalised Anxiety Disorder (GAD). Patients will be randomised to receive one of two doses of BNC210 (300mg or 2000mg) or one of two controls, placebo or 1.5mg Lorazepam.

The study will evaluate the capacity of BNC210 to engage brain systems relevant to anxiety. The endpoints include both significant changes in cerebral perfusion and in task-related brain activity using the emotional faces task during fMRI.

The study is being conducted by Principal Investigator, Professor Allan Young, at The Institute of Psychiatry, Psychology & Neuroscience at King’s College in London. The clinical phase of the study is expected to be completed by Q2 2016 with results due in Q3 2016. Bionomics is also conducting an ongoing Phase Ib multiple ascending dose study (BNC210.005) of BNC210 in healthy human male volunteers. This study is examining the safety and tolerability of multiple doses of BNC210, after repeat dosing for eight days, with secondary endpoints investigating the pharmacokinetic and pharmacodynamic profile of BNC210 and its effect on cognitive functions.

Related organisations